Skip to main content
TipRanks
Go Ultimate75% OFF

Pascal Biosciences Inc (8DZ) Stock Price & Analysis

0 Followers

8DZ Stock Chart & Stats

€0.02€0.01(83.33%)
At close: 2:00 AM GMT+2
€0€0.2€0.4Jul 7Oct 18Oct 31Mar 25Sep 10
Day’s Range
EUR 0.00 - EUR 0.02
52-Week Range
EUR 0.00 - EUR 0.05
Previous Close
EUR 0.01
Volume
N/A
Average Volume (3M)
1,167
Market Cap
EUR 504.21K
Enterprise Value
EUR 1.32M
Total Cash (Recent Filing)
EUR 60.85K
Total Debt (Recent Filing)
EUR 394.63K
Price to Earnings (P/E)
―
Beta
-3.68
Next Earnings
Mar 25, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Manageable Leverage

Moderate leverage and positive equity provide a stronger financial foundation than the company had in earlier periods. This reduces balance-sheet strain, preserves flexibility for operations, and gives management more capacity to address losses without relying entirely on additional borrowing.

Positive Cash Generation

The shift to positive operating and free cash flow is an important improvement in internal funding capacity. If maintained, it can reduce dependence on external financing and support ongoing business activities, although durability remains tied to stabilizing revenue and improving profitability.

Improving Gross Margin

Higher gross margin and a materially smaller EBITDA loss indicate progress in the economics of the business, even though profitability remains negative. Continued improvement could strengthen operating leverage and move the company closer to sustainable earnings if revenue contraction is reversed.

Bears Say

Sharp Revenue Contraction

A sharply contracting top line weakens the company’s ability to absorb fixed operating costs and sustain investment in its business. Persistent revenue pressure would limit the benefit of margin improvements, reduce operating leverage, and make a durable path to profitability more difficult.

Persistent Losses

Ongoing net and operating losses show that the business is not yet converting its activities into sustainable profits. Negative returns on equity can gradually erode financial resources and restrict the company’s ability to reinvest, strengthen its balance sheet, or fund growth internally.

Weakening Cash-Flow Trend

Positive cash flow is tempered by its decline versus the prior period and modest coverage relative to revenue scale. This suggests limited cash-generation resilience, leaving less room to absorb continued operating losses or fund development unless revenue stabilizes and cash conversion improves.

Pascal Biosciences Inc News

8DZ FAQ

What was Pascal Biosciences Inc’s price range in the past 12 months?
Pascal Biosciences Inc lowest stock price was €0.00 and its highest was €0.05 in the past 12 months.
What is Pascal Biosciences Inc’s market cap?
Pascal Biosciences Inc’s market cap is €504.21K.
When is Pascal Biosciences Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Pascal Biosciences Inc’s earnings last quarter?
Pascal Biosciences Inc released its earnings results on Jul 16, 2026. The company reported -€0.001 earnings per share for the quarter.
Is Pascal Biosciences Inc overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Pascal Biosciences Inc pay dividends?
Pascal Biosciences Inc does not currently pay dividends.
What is Pascal Biosciences Inc’s EPS estimate?
Pascal Biosciences Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pascal Biosciences Inc have?
Pascal Biosciences Inc has 39,662,727 shares outstanding.
What happened to Pascal Biosciences Inc’s price movement after its last earnings report?
Pascal Biosciences Inc reported an EPS of -€0.001 in its last earnings report. Following the earnings report the stock price went down -33.333%.
Which hedge fund is a major shareholder of Pascal Biosciences Inc?
Currently, no hedge funds are holding shares in DE:8DZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology